Denali Therapeutics Inc.
DNLI
$15.49
$0.261.71%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -479.03M | -453.94M | -422.77M | -427.49M | -419.65M |
| Total Depreciation and Amortization | 4.16M | 2.14M | 1.09M | 8.55M | 8.50M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 83.00M | 75.44M | 57.05M | 44.08M | 42.82M |
| Change in Net Operating Assets | 42.26M | 10.81M | 16.94M | 12.23M | -22.53M |
| Cash from Operations | -349.62M | -365.54M | -347.69M | -362.64M | -390.86M |
| Capital Expenditure | -18.33M | -18.84M | -15.91M | -13.06M | -11.24M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 460.88M | 402.02M | -72.84M | -174.86M | -169.42M |
| Cash from Investing | 442.55M | 383.18M | -88.76M | -187.92M | -180.66M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -39.13M | -36.70M | -32.34M | -24.02M | -- |
| Issuance of Common Stock | 14.74M | 17.44M | 517.60M | 518.15M | 514.71M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -480.00K | -480.00K | -960.00K | -960.00K | -480.00K |
| Cash from Financing | -24.87M | -19.73M | 484.30M | 493.18M | 514.23M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 68.06M | -2.10M | 47.85M | -57.38M | -57.29M |